Skip to content
TriangleGet started
← Full study record

NCT00866047 · OUTCOME

Overall Survival

A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma · Source last updated 2017-03-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
up to approximately 7 years

What was measured

Time from start of study treatment to date of death due to any cause.

Analysis population: Intention to treat

Groups in this outcome

Brentuximab Vedotin

Brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Brentuximab Vedotin58

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Brentuximab VedotinNANot reported21.3NAInsufficient number of events to estimate median and upper bound
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        Insufficient number of events to estimate median and upper bound
        group Id
        OG000
        lower Limit
        21.3
        upper Limit
        NA
        value
        NA
denoms
  1. counts
    1. group Id
      OG000
      value
      58
    units
    Participants
description
Time from start of study treatment to date of death due to any cause.
dispersion Type
95% Confidence Interval
groups
  1. description
    Brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion
    id
    OG000
    title
    Brentuximab Vedotin
param Type
MEDIAN
population Description
Intention to treat
reporting Status
POSTED
time Frame
up to approximately 7 years
title
Overall Survival
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Independent clinical review pending · Not medical advice